Inicure

Executive Summary

Inicure AB is a Swedish pre-clinical biotechnology company founded in 2018 and headquartered in Stockholm. The company is developing novel small molecule agonists targeting the Formyl Peptide Receptor-1 (FPR1), an innate immune receptor. By activating the host immune system, Inicure aims to combat antibiotic-resistant bacterial infections without directly targeting bacteria, thereby reducing the risk of antimicrobial resistance development. This approach represents a paradigm shift in infectious disease treatment, leveraging immunotherapy to address the growing global threat of multidrug-resistant pathogens. Inicure's platform is based on proprietary chemistry and preclinical validation, positioning it as a potential leader in host-directed therapies for infectious diseases. Although still in early stages, the company's innovative strategy could address significant unmet medical needs. The company is privately held and has not disclosed funding rounds or valuation, suggesting it may be seeking initial capital or partnerships to advance its pipeline.

Upcoming Catalysts (preview)

• Q3 2026Completion of lead optimization and selection of a preclinical candidate60% success
• Q4 2026Presentation of in vivo efficacy data against antibiotic-resistant bacteria at a scientific conference50% success
• Q1 2027Initiation of IND-enabling toxicology studies40% success